|
Stories from the dialysis comunity across the globe.
|
|
FDA: Seizure risk from cefepime in patients with renal impairment. |
 |
 |
|
FDA: The U.S. Food and Drug Administration (FDA) is reminding health care professionals about the need to adjust the dosage of the antibacterial drug cefepime in patients with renal (kidney) impairment. There have been cases of a specific type of seizure called nonconvulsive status epilepticus associated with the use of cefepime, primarily in patients with renal impairment who did not receive appropriate dosage adjustments of cefepime. The Warnings and Precautions and Adverse Reactions sections of the cefepime label are being revised to highlight this risk.
|
|
|
FDA approves new phosphate-free colon cleansing prep. |
|
|
|
FDA: On July 16, the U.S. Food and Drug Administration approved Prepopik (sodium picosulfate, magnesium oxide and citric acid) to help cleanse the colon in adults preparing for colonoscopy. One dose of Prepopik consists of two packets of powder, each dissolved in cold water and taken at separate times. Patients should take Prepopik the night before colonoscopy and the morning of colonoscopy (Split-Dose regimen). If this is not possible, patients may take Prepopik in the afternoon and evening before the colonoscopy (Day-Before regimen).
|
|
Trial of EPO pump underway. |
|
|
|
Business Wire: Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of Biopump(TM), a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the launch of its Phase IIa clinical trial in Israel of EPODUR(TM) Biopumps to treat anemia in patients with end-stage renal disease (“ESRD” or “kidney failure”) on dialysis, through the sustained delivery of erythropoietin (“EPO”). Following the Israeli Ministry of Health’s recent approval of the trial, Medgenics has enrolled and begun to treat the first two dialysis patients ever to receive EPODURE Biopumps.
|
|
|
Are you one of the U.S. top nephrologists? Check the U.S. News and World Report list. |
|
|
|
US News: There are 707 top nephrologists on the list of U.S. News Top Doctors. These physicians were selected based on a peer nomination process. Within this list of the best nephrologists, 109 have been named to a highly selective list of America's Top Doctors (ATD) by achieving national recognition for outstanding work.
|
|
FDA approves second diet drug within a month. |
|
|
|
NPR: After a 13-year hiatus, the Food and Drug Administration gave its OK to the second weight-loss drug in a month. This time it's Qsymia, previously called Qnexa, from Vivus. The pill contains two active ingredients: topiramate, an anti-seizure medicine, and phentermine, a stimulant.
|
|
|
|
|
<< Start < Prev 481 482 483 484 485 486 487 488 489 490 Next > End >>
|
|
Page 481 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
